Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is 1 associated with lower cell-associated HIV RNA and DNA levels as compared with therapy 2 based on protease inhibitors 3

It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress HIV replication. Here, we report the results of two cross-sectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n=100, n=124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either a NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4+ count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically-measured adherence to ART.In both cohorts, levels of CA HIV RNA and DNA strongly correlated (rho=0.70 and rho=0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (padj=0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (padj=0.048 and padj=0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals.All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size.


49
In individuals who are able to adhere to combination antiretroviral therapy (ART), therapy 50 suppresses HIV replication, restores immune function, and prevents the development of AIDS 51 [1]. More than 20 different antiretroviral drugs belonging to six main classes are currently 52 approved for clinical use [2]. Depending on the class, these drugs block different steps of the HIV 53 replication cycle, such as reverse transcription, proviral integration, or virus particle maturation. 54 Current ART regimens typically consist of two nucleotide or nucleoside reverse transcriptase 55 inhibitors (NRTIs) and a third drug of another class, e.g., a non-nucleoside reverse transcriptase 56 inhibitor (NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (INSTI). 57 Despite the efficient suppression of HIV replication, ART is not curative and has to be sustained 58 lifelong. Persistence of viral reservoirs forms the major obstacle to an HIV cure [3]. Viral 59 reservoir markers, such as low-level HIV RNA in plasma (residual viremia) and cell-associated 60 (CA) HIV DNA and RNA, can be measured in most treated individuals with plasma HIV RNA 61 suppressed to below the limit of quantification of commercial assays [4][5][6][7][8]. Although HIV latent 62 reservoirs persist primarily by cell longevity and proliferation [9][10][11], replenishment of the 63 reservoirs by residual virus replication despite ART has been proposed as an alternative 64 mechanism of HIV persistence [12][13][14]. The latter possibility remains a matter of longstanding vs. 13 months, respectively, p<0.0001). In addition, low-level plasma HIV RNA was detectable 229 more frequently in PI-treated than in NNRTI-treated participants (25.0% vs. 9.1%, p=0.04).

230
Other variables, including adherence to ART, did not differ between NNRTI-and PI-treated 231 participants.

232
The median CA HIV RNA and total HIV DNA levels in the AIMS cohort were 1.71 (1.25-2.01) 233 log 10 copies/μg total RNA and 2.41 (1.88-2.79) log 10 copies/10 6 PBMC, respectively. Figure     RNA and DNA. To this end, we compared the HIV markers between these two drugs and PIs 296 ( Figure 3C). While no difference was observed in CA RNA or total DNA levels between 297 efavirenz-and nevirapine-treated participants, CA RNA was significantly lower in participants 298 treated with either of these drugs compared to PI-treated participants and a trend in the same 299 direction was observed for total DNA. Finally, no differences were observed in either CA RNA 300 or total DNA levels between three individual ritonavir-boosted PIs that were used by the majority 301 of PI-treated participants (atazanavir, darunavir, and lopinavir) ( Figure 3D). These results 302 demonstrate that the effects of ART regimens on the CA RNA and DNA levels were ART class-303 specific and not drug-specific. participants for the duration of PI-based or nevirapine-based regimens, but despite this, 319 significant differences were still observed between the nevirapine-and PI-treated groups in total 320 ART duration and duration of plasma HIV RNA suppression. In our study, we reasoned that, in    current ART regimen, prior to the measurements. Effect sizes and 95% confidence intervals for 716 US RNA are plotted as log 10 copies per microgram of total cellular RNA and for total DNA as 717 log 10 copies per million PBMC. Effect sizes were obtained by fitting generalized linear models.

718
Variables associated with HIV RNA or DNA with p values <0.1 in the univariable analyses were 719 included in the multivariable analyses.  RNA: log 10 copies/μg total RNA, total DNA: log 10 copies/10 6 PBMC.   ii Data are medians (interquartile ranges) for continuous variables and numbers (percentages) for discrete variables.
iii Where detectable, plasma HIV RNA was <400 copies/ml for all patients.
iv Adherence was measured electronically.         Regression analyses to identify variables associated with cell-associated HIV unspliced (US) RNA and total HIV DNA levels in the AIMS cohort, taking into account either (A) duration of cumulative virological suppression on ART, or (B) duration of current ART regimen, prior to the measurements. Effect sizes and 95% confidence intervals for US RNA are plotted as log 10 copies per microgram of total cellular RNA and for total DNA as log 10 copies per million PBMC. Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p values <0.1 in the univariable analyses were included in the multivariable analyses. Regression analyses to identify variables associated with cell-associated HIV unspliced (US) RNA and total HIV DNA levels in the AIMS cohort, taking into account both duration of continuous virological suppression on ART and duration of current ART regimen, prior to the measurements. Effect sizes and 95% confidence intervals for US RNA are plotted as log 10 copies per microgram of total cellular RNA and for total DNA as log 10 copies per million PBMC. Effect sizes were obtained by fitting generalized linear models. Variables associated with HIV RNA or DNA with p values <0.1 in the univariable analyses were included in the multivariable analyses. Associations of ART regimen (NNRTI-based vs. PI-based) with the levels of cell-associated HIV unspliced RNA (US RNA) and total HIV DNA in the total pooled cohort. Participants were grouped according to the time of continuous virological suppression: 0-1 years, 2-5 years, 6-9 years, and 10 years or more. Units of measurement are: US RNA: log 10 copies/μg total RNA, total DNA: log 10 copies/10 6 PBMC. Total DNA 0-1 y 2-5 y 6-9 y ≥10 y 0-1 y 2-5 y 6-9 y ≥10 y Figure 3-figure supplement 3. Levels of US RNA and total HIV DNA in participants treated with ART regimens based on efavirenz (EFV), nevirapine (NVP), ritonavir-boosted atazanavir (ATZ/r), ritonavir-boosted darunavir (DRV/r), or ritonavirboosted lopinavir (LPV/r) in the total pooled cohort. Units of measurement are: US RNA: log 10 copies/μg total RNA, total DNA: log 10 copies/10 6 PBMC. Levels of significance were calculated by Kruskal-Wallis tests. Participant numbers per regimen are indicated below the graphs.